Accordingly, all luminal B patients, determined by high levels of Ki-67, undergo anthracycline and taxane chemotherapy [8], and the HER2-positive luminal tumours, considered as luminal B [2, 9], additionally follow the anti-HER2 therapy. The gene discussed is ERBB2; the disease is neoplasm.